1. Home
  2. KNSA vs CTRI Comparison

KNSA vs CTRI Comparison

Compare KNSA & CTRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • CTRI
  • Stock Information
  • Founded
  • KNSA 2015
  • CTRI 1909
  • Country
  • KNSA United Kingdom
  • CTRI United States
  • Employees
  • KNSA N/A
  • CTRI N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • CTRI
  • Sector
  • KNSA Health Care
  • CTRI
  • Exchange
  • KNSA Nasdaq
  • CTRI Nasdaq
  • Market Cap
  • KNSA 1.7B
  • CTRI 1.8B
  • IPO Year
  • KNSA 2018
  • CTRI 2024
  • Fundamental
  • Price
  • KNSA $20.59
  • CTRI $20.33
  • Analyst Decision
  • KNSA Strong Buy
  • CTRI Hold
  • Analyst Count
  • KNSA 5
  • CTRI 7
  • Target Price
  • KNSA $36.60
  • CTRI $18.50
  • AVG Volume (30 Days)
  • KNSA 290.2K
  • CTRI 389.2K
  • Earning Date
  • KNSA 10-29-2024
  • CTRI 02-15-2025
  • Dividend Yield
  • KNSA N/A
  • CTRI N/A
  • EPS Growth
  • KNSA N/A
  • CTRI N/A
  • EPS
  • KNSA N/A
  • CTRI N/A
  • Revenue
  • KNSA $384,098,000.00
  • CTRI $2,585,466,000.00
  • Revenue This Year
  • KNSA $60.05
  • CTRI N/A
  • Revenue Next Year
  • KNSA $36.32
  • CTRI $4.91
  • P/E Ratio
  • KNSA N/A
  • CTRI N/A
  • Revenue Growth
  • KNSA 54.41
  • CTRI N/A
  • 52 Week Low
  • KNSA $16.56
  • CTRI $14.47
  • 52 Week High
  • KNSA $28.15
  • CTRI $28.65
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 40.95
  • CTRI N/A
  • Support Level
  • KNSA $19.97
  • CTRI N/A
  • Resistance Level
  • KNSA $20.85
  • CTRI N/A
  • Average True Range (ATR)
  • KNSA 0.69
  • CTRI 0.00
  • MACD
  • KNSA 0.03
  • CTRI 0.00
  • Stochastic Oscillator
  • KNSA 35.61
  • CTRI 0.00

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About CTRI Centuri Holdings Inc. Common Stock

Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings primarily consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. They operate under two primary lines of business which includes Gas Utility Services and Electric Utility Services it is also their two reportable segments as well.

Share on Social Networks: